<DOC>
	<DOCNO>NCT02907918</DOCNO>
	<brief_summary>The investigator propose influence estrogen receptor ( ER ) signal combine endocrine therapy CDK4/6 inhibition along trastuzumab ER+/ human epidermal growth factor receptor 2 ( HER2 ) + early stage breast cancer .</brief_summary>
	<brief_title>Neoadjuvant Study Palbociclib Combination With Letrozole Trastuzumab Stage II-III ER+ HER2+ Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Newly diagnose clinical stage II III ER+/HER2+ breast cancer complete surgical excision breast cancer neoadjuvant therapy treatment goal . Tumor size least 2 cm one dimension clinical radiographic exam ( World Health Organization ( WHO ) criterion ) . At least 18 year age . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Normal bone marrow organ function define : Leukocytes ≥ 3,000/mcL Absolute neutrophil count ≥ 1,500/mcl Platelets ≥ 100,000/mcl Total bilirubin ≤ institutional upper limit normal ( IULN ) AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 x IULN Creatinine ≤ IULN OR creatinine clearance ≥ 60 mL/min/1.73 m^2 patient creatinine level institutional normal Left ventricular ejection fraction ( LVEF ) ≥ 50 % transthoracic echocardiogram multigated acquisition scan ( MUGA ) Baseline correct QT interval ( QTc ) &lt; 480 ms Women childbearing potential must agree undergo pregnancy test within 14 day study entry agree use adequate contraception ( barrier method birth control , abstinence , hormonal ) prior study entry duration study participation well chemical ovarian suppression goserelin . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . Ability understand willingness sign IRB approve write informed consent document ( legally authorize representative , applicable ) . Prior systemic therapy indexed breast cancer . Indeterminate negative HER2 status . Inflammatory breast cancer . A history malignancy ≤ 5 year diagnosis index BC exception basal cell squamous cell carcinoma skin treat local resection carcinoma situ cervix . Currently receive investigational agent receive within past 28 day . Know HIV positive . Known hepatitis B C infection . A history allergic reaction attribute compound similar chemical biologic composition palbociclib , letrozole , trastuzumab , aromatase inhibitor , monoclonal antibody , agent use study . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . Current use anticipate need food drug know strong CYP3A4 inhibitor ( i.e. , grapefruit juice , verapamil , ketoconazole , miconazole , itraconazole , posaconazole , erythromycin , clarithromycin , telithromycin , indinavir , saquinavir , ritonavir , nelfinavir , lopinavir , atazanavir , amprenavir , fosamprenavir , nefazodone , diltiazem , delavirdine ) inducer ( i.e . dexamethasone , glucocorticoid , progesterone , rifampin , phenobarbital , St. John 's wort ) . Receiving medication ( within last 7 day prior registration ) potential prolong QT interval Any condition impairs ability swallow absorb oral medication ( e.g. , gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affective absorption ) . Pregnant and/or breastfeeding . Women childbearing potential must negative pregnancy test within 14 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>